{"id":182667,"date":"2024-02-14T05:22:39","date_gmt":"2024-02-14T11:22:39","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/02\/new-non-opioid-drug-blocks-pain-signals-before-they-can-reach-brain"},"modified":"2024-02-14T05:22:39","modified_gmt":"2024-02-14T11:22:39","slug":"new-non-opioid-drug-blocks-pain-signals-before-they-can-reach-brain","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/02\/new-non-opioid-drug-blocks-pain-signals-before-they-can-reach-brain","title":{"rendered":"New Non-Opioid Drug Blocks Pain Signals Before They Can Reach Brain"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/new-non-opioid-drug-blocks-pain-signals-before-they-can-reach-brain2.jpg\"><\/a><\/p>\n<p>As the opioid crisis worsens, one Boston-based pharmaceutical company has used some impressive biology to create what it says amounts to a non-addictive, non-opioid painkiller.<\/p>\n<p>As the <a href=\"https:\/\/www.nytimes.com\/2024\/01\/30\/health\/vertex-pain-medicine-non-opioid.html\" class=\"\"><em>New York Times<\/em> reports<\/a>, Vertex Pharmaceuticals seems to have shown some promising results in Phase 3 clinical trials, announced earlier this week <a href=\"https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-positive-results-vx-548-phase-3-program\" class=\"\">in a statement<\/a>, for patients who experienced \u201cmoderate-to-severe acute pain\u201d after getting surgery.<\/p>\n<p>Whereas opioids <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4590096\/\" class=\"\">generally target<\/a> both the brain and the body, which ultimately leads to their addictiveness, non-opioid drugs like Vertex\u2019s VX-548 focus on peripheral nerves, or those outside of the brain and spine, the <em>NYT<\/em> explains. By blocking pain at the source, the logic goes, it can be averted before reaching the brain and developing the kind of feedback loop that lends itself to dependency.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>As the opioid crisis worsens, one Boston-based pharmaceutical company has used some impressive biology to create what it says amounts to a non-addictive, non-opioid painkiller. As the New York Times reports, Vertex Pharmaceuticals seems to have shown some promising results in Phase 3 clinical trials, announced earlier this week in a statement, for patients who [\u2026]<\/p>\n","protected":false},"author":556,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-182667","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/182667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=182667"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/182667\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=182667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=182667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=182667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}